These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 27856630)
1. Prospective Clinical Trial of Ulaner GA; Goldman DA; Corben A; Lyashchenko SK; Gönen M; Lewis JS; Dickler M J Nucl Med; 2017 Jul; 58(7):1037-1042. PubMed ID: 27856630 [No Abstract] [Full Text] [Related]
2. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766 [TBL] [Abstract][Full Text] [Related]
3. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856 [TBL] [Abstract][Full Text] [Related]
12. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma. Jung NY; Kim SH; Choi BB; Kim SH; Sung MS World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560 [TBL] [Abstract][Full Text] [Related]
13. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013 [TBL] [Abstract][Full Text] [Related]
18. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel. García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513 [TBL] [Abstract][Full Text] [Related]
19. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer]. Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556 [TBL] [Abstract][Full Text] [Related]
20. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors. Karan B; Pourbagher A; Torun N J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]